docetaxel + platinum

Docetaxel + platinum refers to a combination chemotherapy regimen consisting of the taxane agent docetaxel and a platinum-based compound (most commonly cisplatin or carboplatin). This combination is primarily used in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC), but may also be used in other solid tumors. Docetaxel acts as an antimitotic agent by stabilizing microtubules and inhibiting their depolymerization, leading to cell cycle arrest and apoptosis. Platinum compounds such as cisplatin or carboplatin form DNA crosslinks that inhibit DNA replication and transcription, resulting in cytotoxicity. The rationale for combining these agents is based on their complementary mechanisms of action and non-overlapping toxicity profiles[2][3]. Clinical studies have shown response rates ranging from 32% to 48% with this regimen in NSCLC patients[2][3].

Other names

docetaxel plus platinumdocetaxel and platinumdocetaxel/cisplatindocetaxel/carboplatin